Moderate-to-Severe Plaque Psoriasis MedDRA version: 20.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Conditions
Interventions
Product Name: ustekinumab
Product Code: FYB202
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: USTEKINUMAB
CAS Number: 815610-63-0
Current Sponsor code: FYB202
C
Sponsors
bioeq GmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who provided written informed consent and who are able to complete study procedures. 2. Patients who are at least 18 years of age at time of screening. 3. Patients with PASI score of at least 12 at screening and at baseline. 4. Patients with involved body surface area of at least 10% at screening and at baseline. 5. Patients with a Physician’s Global Assessment (PGA) score of at least 3 at screening and at baseline by means of a 5-point scoring scale. 6. Patients who are candidates for systemic therapy or phototherapy. 7. Previous failure, inadequate response in the opinion of the investigator, intolerance, or contraindication to at least 1 conventional antipsoriatic systemic therapy. 8. For female patients (except those at least 2 years postmenopausal or surgically sterilised): a negative serum pregnancy test at screening and at baseline. 9. Female patients of childbearing potential with a fertile male sexual partner must use adequate contraception from screening until 4 months after the last dose of study intervention. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device (IUD), combined with at least one of the following forms of contraception: a diaphragm, cervical cap, or a condom. Total abstinence from heterosexual activity, in accordance with the lifestyle of the patient, is acceptable. Female patients must not donate ova starting at screening and throughout the clinical study period and for 4 months after study intervention administration. 9. Male patients who are sexually active with women of childbearing potential must agree they will use adequate contraception if not surgically sterilised and will not donate sperm from the time of screening until 6 months after the last dose of study intervention. Adequate contraception for the male patient and his female partner of childbearing potential is defined as using hormonal contraceptives or an IUD combined with at least one of the following forms of contraception: a diaphragm, cervical cap, or a condom. Total abstinence from heterosexual activity, in accordance with the lifestyle of the patient, is acceptable. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 300 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 92
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, any other skin disease, or other systemic inflammatory autoimmune disorder at the time of the screening and baseline visits that would interfere with evaluations of the effect of study intervention on psoriasis. 2. Patients who have received any topical psoriasis treatment including corticosteroids. 3. Patients who have received the following treatments for psoriasis: a. PUVA phototherapy and/or ultraviolet B phototherapy and/or laser therapy b. Non-biologic psoriasis systemic therapies, tofacitinib, or apremilast c. Adalimumab d. Etanercept or secukinumab e. Infliximab, brodalumab, certolizumab pegol, ixekizumab, golimumab, or alefacept 4. Patients taking drugs that may cause new onset or exacerbation of psoriasis 5. Patients who have received ustekinumab or any biologics directly targeting interleukin (IL) 12 or IL 23. 6. Patients with active infection or history of infections as follows: a. Any active infection for which systemic anti-infectives were used within 4 weeks prior to randomisation b. A serious infection, defined as requiring hospitalisation or intravenous anti-infectives, within 8 weeks prior to randomisation c. Evidence of any clinically relevant bacterial, viral, fungal, or parasitic infection d. Recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary Objective: • Evaluate and compare percent improvement in Psoriasis Area and Severity Index (PASI) score over 12 weeks ;Secondary Objective: Secondary Objectives: • Evaluate and compare the efficacy, safety, and immunogenicity over time • Evaluate and compare ustekinumab trough concentrations (Ctrough) over time ;Primary end point(s): • Percent improvement in PASI score from baseline (week 0) to week 12 ;Timepoint(s) of evaluation of this end point: 12 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Percent improvement in PASI score • Raw PASI score • Proportion of patients with PASI 75 and PASI 90 • Change per Physician's Global Assessment (PGA) • Improvement of Dermatology Life Quality Index (DLQI) total score • Itching Visual Analogue Scale • Relative frequency, nature, and severity of adverse events (AEs) and serious adverse events (SAEs) • Serum trough levels of ustekinumab • Number of patients with antibodies to ustekinumab ;Timepoint(s) of evaluation of this end point: Various endpoints as detailed in the study protocol. | — |
Countries
Estonia, Georgia, Poland, Ukraine
Contacts
Public ContactClinical Trial Information Desk
bioeq GmbH
Outcome results
None listed